One approach could be to evaluate the expression levels of the identified prognostic genes (e.g. CRLF2, HSP90AA1, MAP2K1 etc.)in a small set of clinical HNSCC samples using RT-qPCR. The gene discussed is MAP2K1; the disease is head and neck squamous cell carcinoma.